Targeting Inflammation-Oxidative Stress Crosstalk: Advances and Challenges in Nanocarrier-Based Interventional Strategies for Pulmonary Arterial Hypertension
Abstract
Pulmonary arterial hypertension (PAH) is a cardiovascular disease characterized by a hidden or insidious onset with symptoms including dyspnea and heart failure, which can result in sudden death. Inflammation and oxidative stress are key factors in the pathogenesis of PAH. Hence, anti-inflammatory and antioxidant agents are promoted as therapeutically beneficial. However, the efficacy and safety of these therapeutics are limited by poor solubility and stability, short half-life, lack of targeting capability, and significant side effects. The pulmonary vasculature of patients with PAH exhibits highly heterogeneous blood flow distribution, characterized by reduced wall shear stress and vortex formation at pulmonary artery bifurcations. Abnormal shear stress impairs endothelial function and induces progressive pulmonary vascular remodeling. Combined with endothelial barrier dysfunction, these hemodynamic alterations collectively govern the adhesion, retention and transmural transport of nanocarriers within diseased blood vessels. Nanocarriers (NCs) including liposomes, polymeric and exosomes, through intelligent responsiveness, combination therapy, and personalized and precision delivery strategies, can significantly enhance drug stability, prolong half-life, achieve specific targeting of pulmonary lesions, and reduce side effects. In addition, local administration methods, such as aerosol inhalation and intratracheal instillation, can achieve efficient drug accumulation in the…
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.